SciBase Partner With a Large Health Care Group in Los Angeles, Unified Health, and Receives a First Order
SciBase Partner With a Large Health Care Group in Los Angeles, Unified Health, and Receives a First Order
STOCKHOLM, June 28, 2024 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), SciBase, a leading developer of augmented intelligence-based solutions for skin disorders announced today that it continues to expand in California with a collaboration agreement with Unified Health. Unified Health has nine clinics in Southern California.
2024年6月28日，瑞典斯德哥尔摩/PRNewswire——皮肤科技公司SciBase Holding AB（以下简称“SciBase”）（斯德哥尔摩证券交易所：SCIB）SciBase是一家领先的皮肤疾病增强智能解决方案开发商，宣布今天与Unified Health达成合作协议，继续在加利福尼亚州扩张。Unified Health在加州南部拥有九家诊所。
"At Unified Health, we believe in providing our patients with exceptional medical care and access to the most advance medical technology. Our experienced team of providers are committed to delivering the highest quality of dermatological care to our patients, especially when it comes to the earliest detection possible of melanoma - the deadliest form of skin cancer. For these reasons, we are excited to use Nevisense and believe it will help us improve outcomes for our patients," says Michael Lin, MD, Board-Certified Dermatologist and Founder of Unified Health.
“在Unified Health，我们致力于为患者提供卓越的医疗保健和最先进的医疗技术。我们有经验丰富的医生团队致力于提供最高质量的皮肤病医疗保健，尤其是在病人早期发现黑色素瘤——最致命的皮肤癌症的情况下。因此，我们很高兴使用Nevisense，并相信它将有助于提高病人的预后，”Unified Health的创始人和董事会认证皮肤科医生迈克尔·林博士说。
"SciBase and Unified Health are well aligned with a shared mission to provide clinicians with early detection of melanoma solutions that can drive improved patient outcomes," says Pia Renaudin, CEO of SciBase. "We are encouraged to see more patients getting access to our point-of-care technology that enables the earliest detection possible of melanoma when it is almost 100% curable."
“SciBase和Unified Health的愿景相同，目标是为诊所提供早期检测黑色素瘤的解决方案，以推动改善患者预后，”SciBase的首席执行官皮亚·雷诺丹说。“我们很高兴看到更多的病人获得我们的门诊技术，这使得我们能够在黑色素瘤几乎可以百分之百治愈的情况下尽早地进行检测。”
For additional information, please contact:
Pia Renaudin, VD, tel. +46732069802, e-mail: [email protected]
欲了解更多信息，请联系:
Pia Renaudin，VD，电话+46 732069802，电子邮件：[email protected]
Certified Advisor (CA):
Vator Securities
Tel: +46 8 580 065 99
Email: [email protected]
认证顾问（CA）：
Vator Securities
电话：+46858006599
电子邮件：[email protected]
About SciBase:
关于SciBase：
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management.
SciBase是一家全球性医疗技术公司，专注于皮肤疾病的早期检测和预防。SciBase开发和商业化Nevisense，这是一种独特的点对点平台，结合了人工智能和先进的电阻抗谱技术，提高了诊断准确性，确保积极的皮肤健康管理。
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
我们致力于减少患者的痛苦，使临床医生通过及时检测和干预来改善和挽救生命，并降低医疗保健成本。
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
SciBase在瑞典斯德哥尔摩的卡罗林斯卡学院进行了20多年的研究，是皮肤病学进展的领先者。
The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015. Learn more at . All press releases and financial reports can be found here:
该公司自2015年6月2日在纳斯达克创业板上市。请访问了解更多信息。所有新闻发布和财务报告都可以在此找到：
This information was brought to you by Cision
本信息由Cision提供
The following files are available for download:
以下文件可供下载：
|
PM_UH eng |
|
PM_UH eng |